{"id":"gallopamil","rwe":[],"tags":[{"label":"gallopamil","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Sodium channel alpha subunits; brain (Types I, II, III)","category":"target"},{"label":"SCN1A","category":"gene"},{"label":"SCN2A","category":"gene"},{"label":"SCN3A","category":"gene"},{"label":"C08DA02","category":"atc"},{"label":"Active","category":"status"},{"label":"Calcium Channel Blockers","category":"pharmacology"},{"label":"Calcium-Regulating Hormones and Agents","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Membrane Transport Modulators","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"methoxyverapamil","offLabel":[],"synonyms":["gallopamil","methoxyverapamil","gallopamil hydrochloride","gallopamil HCl"],"timeline":[],"aiSummary":"Methoxyverapamil is a small molecule. It has been studied in clinical trials for various conditions, including endometriosis, obesity, asthma, and influenza A virus.","approvals":[],"brandName":"Methoxyverapamil","ecosystem":[],"mechanism":{"target":"Sodium channel alpha subunits; brain (Types I, II, III)","targets":[{"gene":"SCN1A","source":"DrugCentral","target":"Sodium channel alpha subunits; brain (Types I, II, III)","protein":"Sodium channel protein type 1 subunit alpha"},{"gene":"SCN2A","source":"DrugCentral","target":"Sodium channel alpha subunits; brain (Types I, II, III)","protein":"Sodium channel protein type 2 subunit alpha"},{"gene":"SCN3A","source":"DrugCentral","target":"Sodium channel alpha subunits; brain (Types I, II, III)","protein":"Sodium channel protein type 3 subunit alpha"}],"modality":"Small Molecule","drugClass":"gallopamil","explanation":"Imagine your brain is like a city with many streets and intersections. Sodium channels are like traffic lights that help control the flow of electrical signals. When these channels get stuck in the 'on' position, it can cause problems. Methoxyverapamil acts like a traffic cop, blocking these channels to help restore normal traffic flow and reduce symptoms.","oneSentence":"Methoxyverapamil blocks sodium channels in the brain to reduce abnormal electrical activity.","technicalDetail":"Methoxyverapamil selectively binds to and blocks sodium channel alpha subunits (Types I, II, III) in the brain, thereby reducing the influx of sodium ions and modulating abnormal electrical activity."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1275","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=GALLOPAMIL","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=GALLOPAMIL","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T14:56:31.493460","biosimilars":[],"competitors":[{"drugName":"verapamil","drugSlug":"verapamil","fdaApproval":"1981-08-12","genericCount":37,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"gallopamil","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"verapamil","brandName":"verapamil","genericName":"verapamil","approvalYear":"1981","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07262710","phase":"","title":"Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","startDate":"2025-12-01","conditions":["Post-stroke Pneumonia"],"enrollment":13656,"completionDate":"2026-08-19"},{"nctId":"NCT02659735","phase":"PHASE1","title":"A Study to Assess the Relative Oral Bioavailability of JNJ-63623872 Administered as Oral Concept Formulations Compared to the Current Tablet Formulation","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-12","conditions":["Influenza A Virus"],"enrollment":90,"completionDate":"2016-04"},{"nctId":"NCT01371877","phase":"NA","title":"The Role of Vitamin D in Chronic Urticaria and Angioedema Treatment","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2011-11-01","conditions":["Urticaria","Angioedema","Hives","Swelling"],"enrollment":42,"completionDate":"2013-09-01"},{"nctId":"NCT03686150","phase":"NA","title":"Vitamin D Oral Replacement in Asthma","status":"COMPLETED","sponsor":"IDeA States Pediatric Clinical Trials Network","startDate":"2019-01-30","conditions":["Asthma","Vitamin D Deficiency","Pediatric Obesity"],"enrollment":112,"completionDate":"2021-09-30"},{"nctId":"NCT01992263","phase":"NA","title":"Vitamin D Supplementation and TB","status":"UNKNOWN","sponsor":"Cornell University","startDate":"2021-06","conditions":["Tuberculosis","Vitamin D","Immunity"],"enrollment":200,"completionDate":"2023-02"},{"nctId":"NCT01655810","phase":"NA","title":"Vitamin D, Cardiovascular Disease, and African Americans","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2012-08-13","conditions":["Vitamin D Deficiency","Type 2 Diabetes Mellitus","Cardiovascular Disease"],"enrollment":86,"completionDate":"2018-02-09"},{"nctId":"NCT02370550","phase":"PHASE4","title":"Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2015-03","conditions":["Sjogren's Syndrome"],"enrollment":240,"completionDate":"2021-12"},{"nctId":"NCT03649620","phase":"NA","title":"Efficacy and Safety of Unripe Bokbunja Extract on Improvement of Blood Cholesterol","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2016-12","conditions":["Blood Cholesterol"],"enrollment":80,"completionDate":"2018-02"},{"nctId":"NCT00896428","phase":"PHASE2","title":"Effects of Gallopamil in Severe Asthma","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2009-12","conditions":["Asthma"],"enrollment":31,"completionDate":"2012-11"},{"nctId":"NCT01447433","phase":"PHASE4","title":"Effect of Calcium + Vitamin D Supplementation on Weight Management in Very-low Calcium Consumers","status":"COMPLETED","sponsor":"Changhai Hospital","startDate":"2011-04","conditions":["Obesity","Overweight"],"enrollment":53,"completionDate":"2012-02"},{"nctId":"NCT00868907","phase":"PHASE1","title":"Study Assessing Dosing Time and Calcium and Vitamin D on the Relative BA of 35 mg DR Risedronate Dosed With Food","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2009-03","conditions":["Healthy"],"enrollment":101,"completionDate":"2009-04"},{"nctId":"NCT00654524","phase":"PHASE4","title":"Randomized Study of Gonadotropin-releasing-hormone Agonist (GnRH-a) or Expectant Management for Endometriosis","status":"UNKNOWN","sponsor":"Zhejiang University","startDate":"2008-03","conditions":["Endometriosis"],"enrollment":60,"completionDate":"2010-12"},{"nctId":"NCT00441246","phase":"PHASE4","title":"Phase 4 Study - Mucinex D as Adjunct Therapy","status":"COMPLETED","sponsor":"Adams Respiratory Therapeutics","startDate":"2007-02","conditions":["Acute Respiratory Infection","Bronchitis","Rhinosinusitis"],"enrollment":600,"completionDate":"2007-07"},{"nctId":"NCT00353054","phase":"PHASE4","title":"Effect of Calcium/Vitamin D Supplementation on Body Weight and Fat Loss.","status":"COMPLETED","sponsor":"Laval University","startDate":"2003-01","conditions":["Obesity","Overweight"],"enrollment":80,"completionDate":"2005-07"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"NUI":"N0000166522","NDDF":"004173","UNII":"39WPC8JHR8","CHEBI":"CHEBI:34772","INN_ID":"4318","RXNORM":"439837","UMLSCUI":"C0016986","ChEMBL_ID":"CHEMBL51149","KEGG_DRUG":"D08009","DRUGBANK_ID":"DB12923","PUBCHEM_CID":"1234","SNOMEDCT_US":"703433005","SECONDARY_CAS_RN":"16662-46-7","MESH_DESCRIPTOR_UI":"D005711"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"1.8 hours","clearance":"14.3 mL/min/kg","fractionUnbound":"0.07%","volumeOfDistribution":"1.75 L/kg"},"publicationCount":363,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"C08DA02","allCodes":["C08DA02"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}